For the 25 patients with crizotinib-pretreated ALK+ NSCLC treated at 180 mg once daily with 7-day lead-in at 90 mg, median PFS was 14.7 months (95% CI: 9.2–27.1), with PFS rates of 13% (95% CI: 2–34) at 3 years and 13% (95% CI: 2–34) at 5 years (Table 1). Here, ALK is linked to non-small cell lung carcinoma.